AUXLY REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES OUTLOOK FOR 2023

Rhea-AI Summary

Auxly Cannabis Group reported financial results for the year ending December 31, 2022, with total net revenues reaching $94.4 million, a 13% increase from 2021. The company achieved an adjusted EBITDA of negative $16.9 million, improving by $4.8 million year-over-year. Despite a net loss of $130.3 million, management highlighted progress in margins and strategic product focus, especially in dried flower and pre-roll categories. Total assets decreased to $331.8 million, with debt rising slightly to $174.5 million.

Auxly retained its position as the #1 licensed producer for Cannabis 2.0 products in Canada while adapting to market challenges.

Positive

• Total net revenues increased to $94.4 million, up 13% from 2021.
• Adjusted EBITDA improved by $4.8 million year-over-year, reaching negative $16.9 million.
• Maintained leadership in Cannabis 2.0 product sales in Canada for three consecutive years.
• Successfully integrated Auxly Leamington, improving product quality and lowering costs.
• Achieved a gross profit margin of 17%, with significant cost reductions in SG&A.

Negative

• Net loss attributable to shareholders increased to $130.3 million from $33.7 million in 2021.
• Gross profit decreased by $2.8 million compared to 2021, leading to a lower gross profit margin of 17%.
• Total assets fell by $118.6 million year-over-year, indicating a shrinking balance sheet.
• Impairment losses included approximately $67.2 million related to asset closures.

TORONTO, March 31, 2023 /PRNewswire/ - Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) ("Auxly" or the "Company") today released its financial results for the three and twelve months ended December 31, 2022. These filings and additional information regarding Auxly are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars except common shares ("Shares") and per Share amounts.

2022 Highlights

• Total net revenues of $94.4 million in 2022, an increase of $10.6 million or 13% compared to 2021;
• Made significant improvements to Adjusted EBITDA in the fourth quarter to negative $0.8 million, due to improved margins and lower SG&A, with momentum continuing into 2023;
• Fourth quarter total net revenues of $24.7 million, approximately $4.6 million lower than the same period in 2021, however $4.9 million or 20% greater than Q3 2022;
• Retained the #1 LP position in Canada for Cannabis 2.0 product sales for the third consecutive year, while improving sales of dried flower and pre-roll products, exiting the year with positive momentum as the #5 LP¹ by share of market;
• Successfully integrated Auxly Leamington and continuously improved product quality during 2022; and leveraged Leamington's large-scale cultivation to introduce new successful strains to the market while continuing to drive down costs to become one of the lowest cost facilities in the country;
• Rationalized assets and product SKUs to improve financial performance and used non-core asset sale proceeds to further strengthen the balance sheet;
• Recorded non-cash impairment of approximately $25.7M related to the closure of Auxly Annapolis and Auxly Annapolis OG cultivation facilities during Q1 of 2022 and $45 million in the third quarter of 2022 related to impairment of goodwill and other assets.

Financial Highlights

For the years ended December 31:
(000's)		2022		2021		2020		Change 2022		Change 2021
Total net revenues		94,472		83,829		46,719		10,643		37,110
Net income/(loss)*		(130,293)		(33,739)		(85,426)		(96,554)		51,687
Net income/(loss) from continuing operations*		(130,293)		(45,895)		(83,889)		(84,398)		37,994
Adjusted EBITDA**		(16,878)		(21,672)		(28,523)		4,794		6,851
Weighted average shares outstanding		889,871,187		783,379,798		631,528,750		106,491,389		151,851,048
As at December 31:
(000's)		2022		2021		2020		Change 2022		Change 2021
Cash and equivalents	$	14,636	$	14,754	$	20,657	$	(118)	$	(5,903)
Total assets	$	331,820	$	450,422	$	378,963	$	(118,602)	$	71,459
Debt***	$	174,475	$	168,809	$	114,825	$	5,666	$	53,984

*Attributable to shareholders of the Company.

**Adjusted EBITDA is a Non-IFRS financial measure. Refer to the Non-GAAP Measures.

***Debt is a supplementary financial measure. Refer to the Non-GAAP Measures.

                   

 

Results of Operations

For the years ended December 31:
(000's)	2022	2021
CONTINUING OPERATIONS
Revenues
Revenue from sales of cannabis products	$        138,885	$         120,824
Excise taxes	(44,413)	(36,995)
Total net revenues	94,472	83,829
Costs of sales
Costs of finished cannabis inventory sold	70,262	62,754
Biological asset impairment	704	-
Inventory (gain)/impairment	10,732	3,264
Gross profit/(loss) excluding fair value items	12,774	17,811
Unrealized fair value gain/(loss) on biological transformation	28,518	2,384
Realized fair value gain/(loss) on inventory	(24,780)	(905)
Gross profit	16,512	19,290
Expenses
Selling, general, and administrative expenses	46,649	44,288
Equity-based compensation	4,023	1,433
Depreciation and amortization	14,816	12,507
Interest expense	21,578	17,668
Total expenses	87,066	75,896
Other income/(loss)
Fair value gain/(loss) for financial instruments accounted under FVTPL	-	6
Interest and other income	337	1,591
Impairment of assets	(67,180)	(11,426)
Gain/(loss) on settlement of assets and liabilities and other expenses	(2,231)	20,289
Gain on disposal of assets held for sale	2,150	-
Gain/(loss) on disposal of subsidiary	-	1,355
Share of gain/(loss) on investment in joint venture	-	(4,661)
Foreign exchange gain/(loss)	923	(788)
Total other income/(loss)	(66,001)	6,366
Net loss before income tax	(136,555)	(50,240)
Income tax recovery	6,262	4,330
Net loss from continuing operations	$      (130,293)	$         (45,910)
Net income/(loss) from discontinued operations	-	12,156
Net income/(loss)	$      (130,293)	$         (33,754)
Net income/(loss) attributable to shareholders of the Company	$      (130,293)	$         (33,739)
Net loss attributable to non-controlling interest	-	(15)
Adjusted EBITDA	$        (16,878)	$         (21,672)
From continuing operations	$            (0.15)	$             (0.06)
From discontinued operations	-	0.02
Net income/(loss) per common share (basic and diluted)	$            (0.15)	$             (0.04)
Weighted average shares outstanding (basic and diluted)	889,871,187	783,379,798

 

Hugo Alves, CEO of Auxly, commented: "The Canadian cannabis industry faced numerous challenges in 2022 and Auxly was not immune to their impacts. To better position the Company within current industry realities, we adapted our strategy in the third quarter by streamlining our focus to the three largest Canadian product categories of dried flower, pre-rolls, and vapes, leveraging our large-scale Leamington facility to deepen our competitive advantage and refining our cost structure. Our efforts have yielded positive results, including our first significant wholesales of bulk dried flower from Auxly Leamington, improved net revenues and blended margins, and reductions in SG&A during the fourth quarter. We also internalized our sales team to improve relationships with retailers, strengthen distribution, and obtain new dried flower and pre-roll listings to increase category breadth and set the stage for further growth in 2023. We are encouraged by our recent achievements and remain dedicated to delivering further improvements in financial performance. I want to thank our talented team members for their continued commitment to Auxly's success."

Net Revenues

For the year ended December 31, 2022, net revenues were $94.5 million as compared to $83.8 million during the same period in 2021. Revenues for 2022 were comprised of approximately 42% in sales of dried flower and pre-roll Cannabis Products, with the remainder from oils and Cannabis 2.0 Product sales. Net revenues included wholesale bulk flower sales of approximately $3.2 million in the fourth quarter, contributing towards the Company's overall shift to increased sales of Cannabis 1.0 Products, which represented approximately 48% of net revenues during the quarter. For the third year, Auxly continued its leadership in national sales of Cannabis 2.0 Products, while increasing its share of market for Cannabis 1.0 Products over the year from 2.5% to 3.7%¹.

Consistent with prior periods, as the Company does not participate in the Quebec market, approximately 85% of cannabis sales in 2022 originated from sales to British Columbia, Alberta and Ontario.

Gross Profit

Auxly realized a gross profit of $16.5 million in 2022, a decrease of $2.8 million as compared to 2021, which includes the impacts of non-cash impairments and fair value adjustments. The Gross Profit Margin for 2022 was 17% versus 23% in 2021. Excluding non-cash amounts, the Cost of Finished Cannabis Inventory Sold Margin improved to 26% versus 25% in 2021, while increasing from 23% in the first quarter of 2022 to 30% in the fourth quarter as a result of a higher proportion of Cannabis 1.0 Products sold by the Company utilizing low-cost cannabis cultivated at Auxly Leamington, and the streamlining of Cannabis 2.0 SKUs and operating costs.

Following the acquisition of Auxly Leamington in November 2021, the Company recognizes gross profit or loss from Auxly Leamington as part of the costs of finished cannabis inventory sold only as product is sold to the Company's customers after being further processed by Auxly Ottawa or Auxly Charlottetown. Realized and unrealized fair value gains and losses reflect accounting treatments associated with Auxly Leamington cultivation and sales. Prior to the acquisition of Auxly Leamington, the net operating results of Auxly Leamington were recorded in other income and expenses on an equity basis in proportion to the Company's ownership in the joint venture.

Biological and inventory impairments during the year were $11.4 million as compared to $3.3 million in 2021, primarily as a result of charges related to the closure of the Auxly Annapolis facilities of $5.0 million in the first quarter of 2022, certain third-party product write-offs, and as a result of SKU rationalization and run-off, and product not meeting quality specifications.

Total Expenses

Selling, general and administrative expenses ("SG&A") are comprised of wages and benefits, office and administrative, professional fees, business development, and selling expenses. SG&A expenses were $46.7 million during 2022, a $2.4M or 5% increase over 2021, which includes the full year impact of the addition of Auxly Leamington expenditures.

Wages and benefits were $18.7 million for the year, as compared to $17.8 million for the same period of 2021. The net increase is primarily due to the addition of Auxly Leamington, partially offset by reductions associated with the closure and sale of the Auxly Annapolis and Auxly Annapolis OG facilities and measures taken after the third quarter to reduce overhead in the rest of the organization.

Office and administrative expenses were $11.6 million for the year, decreasing by $2.0 million compared to the same period in 2021. The decreased expenditures primarily relate to higher product cost absorption, reduced waste and the timing and cost associated with product innovation, partially offset by the inclusion of Auxly Leamington.

Auxly's professional fees were $2.9 million for 2022, the same as the prior year. Professional fees incurred primarily related to accounting fees, regulatory matters, reporting issuer fees, and legal fees associated with certain corporate activities.

Business development expenses were $0.3 million for the year ended December 31, 2022, consistent with the same period in 2021. These expenses have been nominal during the year due to the COVID-19 pandemic and primarily relate to acquisition, business development and travel related expenses.

Selling expenses were $13.1 million for 2022, an increase of $3.5 million over 2021, as a result of cannabis sales activities comprised of brokerage fees, Health Canada fees related to higher revenues, and increased marketing initiatives for Cannabis Products.

Equity-based compensation for the year ended December 31, 2022, was $4.0 million, an increase of $2.6 million over 2021, primarily reflecting the impact of restricted share units ("RSU") granted in June 2022, in respect of services provided by employees in 2021. The RSU charge is primarily determined by the number of units granted, vesting periods and forfeiture assumptions, and the Share price at the time of grant. Equity-based compensation includes expenses related to options which are primarily determined as a function of the number of grants, the weighted average aging of the grants and the share price at the time of grant.

Depreciation and amortization expenses were $14.8 million for the year representing an increase of $2.3 million over 2021, primarily related to additional capital expenditures and the inclusion of Auxly Leamington in 2022.

Interest expenses were $21.6 million in 2022 as compared to $17.7 million during the prior year. The increase in expense is primarily a result of the inclusion of Auxly Leamington and the impact of rising interest rates where such obligations are subject to variable charges. Interest expense includes accretion on the convertible debentures and interest paid in kind on the $123 million Imperial Brands Debenture. Interest payable in cash was approximately $6.7 million for the year.

Total Other Incomes and Losses

Total other incomes and losses for the year were a net loss of $66.0 million primarily due to the third quarter impairment of goodwill and other assets of $45 million, comprised of $24.8 million towards goodwill, $13.2 million towards intangible assets, $2.2 million towards other receivables, and $4.8 million of impairment losses towards long-term assets, including property, plant and equipment. In addition, during the first quarter of 2022, an impairment of long-term assets of $12.9 million and intangible assets and goodwill of $10.8 million related to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities, respectively, where the carrying value exceeds the fair value less cost to sell.

In 2022, foreign exchange gains were $0.9 million as compared to a loss of $0.8 million in 2021. Auxly is exposed to foreign exchange fluctuations from the U.S. dollar to CAD dollar exchange rate primarily related to inventory, capital purchases and Inverell net assets.

Net Income and Loss

Net losses attributable to shareholders of the Company for the year ended December 31, 2022 were $130.3 million, net of income tax recoveries of $6.3 million, representing a net loss of $0.15 per share on a basic and diluted basis. The change in net loss in 2022 as compared to 2021 was primarily driven by changes in total other incomes and losses in 2022 as compared to net gains recorded in 2021.

Adjusted EBITDA

Adjusted EBITDA during the year ended December 31, 2022 was negative $16.9 million, an improvement of $4.8 million over the same period of 2021, primarily as a result of improvements realized during the fourth quarter of 2022.

Discontinued Operations

On May 27, 2021, the Company announced that it had reached an agreement to sell KGK to Myconic Capital Corp. (now Wellbeing Digital Sciences Inc.) ("Wellbeing"), and on June 2, 2021, completed the sale of KGK to Wellbeing. As a result of the sale, results from operations and cash flows from KGK have been presented as discontinued operations, as applicable, on a retrospective basis.

Outlook 

In 2022, we committed to building on our success as a Canadian market leader. We planned on driving organic growth through continued innovation, increasing brand traction, and strengthening distribution, while prioritizing operational efficiencies and profitability. Our high-level objectives for 2022 were:

• Improve revenue and Gross Profit Margin to achieve positive Adjusted EBITDA
• Our key priority in 2022 was to achieve Adjusted EBITDA profitability by continuing to grow top line revenue while enhancing Gross Profit Margins through leveraging the increasing flower output from our Auxly Leamington facility, focused and differentiated brand and product offerings, increased depth and breadth of distribution, and cost optimization through investments in automation to increase production capabilities and efficiency and continuous improvement initiatives.

• Win with consumers and increase brand traction
• We continue to be deeply committed to understanding our targeted consumers and to developing products and brands that help them live happier lives. Driven by deep consumer insights, we will continue to evolve our brand portfolio to earn and maintain the trust and loyalty of our customers and consumers and be the choice of consumers in-store. We will service the evolving preferences of our consumers by bringing new and innovative branded products to market and ensuring that our consumers can access those products broadly and reliably.

Looking back on the year, the Canadian cannabis industry continued to face challenges posed by increasing competition and fragmentation, oversupply of cannabis, high taxation, restrictive regulations, a robust illicit market and severe price compression which were further exacerbated by inflation, global conflict, negative macroeconomic impacts from the COVID-19 pandemic, global supply chain disruptions, and constrained capital markets.

In light of these challenges, we adapted our approach, and at the end of the third quarter, streamlined our product assortment to run off certain low-margin or low-demand SKUs and increased our focus on the dried flower, pre-roll and vape product categories. Concurrently, we reduced costs throughout the organization, and internalized our sales team providing us with a sales team that focuses exclusively on our brands and products when communicating with our retail partners. While we did not meet all of our objectives for 2022, we are pleased with the progress made during the year and, in particular, with the impact that our actions taken at the end of the third quarter have had on our business. We have seen improvements in our margins, our fourth quarter sales (even with fewer SKUs), especially in the key dried flower and pre-roll categories; and material improvements in our Adjusted EBITDA resulting from significant reductions in our supporting cost structure.

As a backdrop to the year ahead, we have been working hard on updating and expanding our dried flower and pre-roll product portfolio utilizing Auxly Leamington's competitive advantage of high-quality, large-scale and low-cost cultivation. Starting in 2023, we have increased our listed flower SKUs by 60% and pre-roll SKUs by 50% as compared to September 30, 2022. We are entering 2023 with improved earnings performance, increased focus on key product formats, lowered costs and increased efficiency which we expect will yield positive results. With these actions in mind, our goals for the coming year are broadly defined below:

• Increase net revenues by 15%, with a focus on key product categories, enhanced by strategic expansion of our product portfolio, while supporting strong retail distribution through our internal sales team.
• Continue to leverage Auxly Leamington's large-scale, low-cost cultivation facility and the Company's manufacturing automation to increase blended Cost of Finished Cannabis Inventory Sold Margin to an average of 35-40%.
• Vigorously manage SG&A as a percentage of net revenues to keep it below 40%, further building upon savings realized in Q4 2022.
• Prudently manage the Company's balance sheet and streamline assets where possible.

We believe we have an achievable plan built upon proven demand for our products, outstanding employees, top-tier assets and an underlying desire to continue to put our consumers first by delivering safe, effective, high-quality products that address their evolving needs and preferences and help them live happier lives.

Non-GAAP Measures

Please see the Company's MD&A for the three and twelves months ended December 31, 2022, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

Financial Measures

EBITDA and Adjusted EBITDA

These are non-GAAP measures used in the cannabis industry and by the Company to assess operating performance removing the impacts and volatility of non-cash adjustments. The definition may differ by issuer. The Adjusted EBITDA reconciliation is as follows:

(000's)	Q4/22	Q3/22	Q2/22	Q1/22	Q4/21	Q3/21	Q2/21	Q1/21
Net loss from continuing operations	$  (16,056)	$ (60,102)	$  (14,289)	$  (39,846)	$  (18,376)	$  (13,527)	$    (3,685)	$  (10,322)
Interest expense	5,655	5,507	5,336	5,080	4,348	3,932	4,787	4,601
Interest income	(63)	(105)	(84)	(85)	(308)	(436)	(431)	(416)
Income tax recovery	(1,112)	(2,110)	(85)	(2,955)	-	-	(4,291)	(39)
Depreciation and amortization included in cost of sales	1,296	681	2,180	1,211	689	386	326	141
Depreciation and amortization      included in expenses	2,791	3,525	3,900	4,600	5,678	2,223	2,174	2,432
EBITDA	(7,489)	(52,604)	(3,042)	(31,995)	(7,969)	(7,422)	(1,120)	(3,603)
Impairment of biological assets	-	-	-	704	-	-	-	-
Impairment of inventory	2,062	2,014	1,778	4,878	2,194	716	124	230
Unrealized fair value loss / (gain) on      biological transformation	(2,814)	(7,496)	(11,735)	(6,473)	(1,462)	(352)	(315)	(255)
Realized fair value loss / (gain) on      inventory	7,382	8,175	6,898	2,325	904	1	1	(1)
Restructuring related costs	-	193	-	-	-	-	-	-
Equity-based compensation	429	475	2,916	203	212	55	960	206
Fair value loss / (gain) for financial instruments accounted under FVTPL	-	-	-	-	408	(223)	(75)	(116)
Impairment of assets	676	42,831	-	23,673	-	60	11,366	-
(Gain) / loss on settlement of assets, liabilities and disposals	(1,330)	1,574	(163)	-	815	(1,396)	(16,995)	(4,068)
Share of loss on investment in joint      venture	-	-	-	-	(1,387)	3,095	2,494	459
Foreign exchange loss / (gain)	301	(938)	(647)	361	242	(633)	571	608
Adjusted EBITDA	$       (783)	$    (5,776)	$    (3,995)	$    (6,324)	$    (6,043)	$    (6,099)	$    (2,989)	$    (6,540)

 

Supplementary Financial Measures

Cost of Finished Cannabis Inventory Sold Margin

"Cost of Finished Cannabis Inventory Sold Margin" is a supplementary financial measure and is defined as Cost of Finished Cannabis Inventory Sold divided by net revenues.

Gross Profit Margin

"Gross Profit Margin" is defined as gross profit divided by net revenues. Gross Profit Margin is a supplementary financial measure.

Debt

"Debt" is defined as current and long-term debt and is a supplementary financial measure. It is a useful measure in managing our capital structure and financing requirements.

Conference Call

Auxly's management team will host a conference call today, Monday, April 3, 2023, at 10:00 a.m. EST to discuss its financial results. Participants can access the conference call by telephone by dialing: 1-888-664-6383 or by audio webcast at: https://app.webinar.net/KV4LpqozBOn.

For those unable to participate in the conference call at the scheduled time, it will be available for replay on the Company's website within 24 hours after the conclusion of the call.

ON BEHALF OF THE BOARD
"Hugo Alves" CEO

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a leading Canadian consumer packaged goods company in the cannabis products market, headquartered in Toronto, Canada. Our focus is on developing, manufacturing and distributing branded cannabis products that delight our consumers.

Our vision is to be a leader in branded cannabis products that deliver on our consumer promise of quality, safety and efficacy.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Notice Regarding Forward Looking Information:

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the proposed operation of Auxly and its subsidiaries; the intention to grow the business, operations and existing and potential activities of Auxly; the impact of the COVID-19 pandemic on the Company's current and future operations; the Company's execution of its innovative product development, commercialization strategy and expansion plans; the Company's intention to introduce innovative new cannabis products to the market and the timing thereof; the anticipated benefits of the Company's partnerships, research and development initiatives and other commercial arrangements; the anticipated benefits of the Company's acquisition of Auxly Leamington; the expectation and timing of future revenues and of positive Adjusted EBITDA; expectations regarding the Company's expansion of sales, operations and investment into foreign jurisdictions; future legislative and regulatory developments involving cannabis and cannabis products; the timing and outcomes of regulatory or intellectual property decisions; the relevance of Auxly's subsidiaries' current and proposed products with provincial purchasers and consumers; consumer preferences; political change; competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: the Company will be able to execute on its business strategy; Auxly's subsidiaries are able to obtain and maintain the necessary governmental and regulatory authorizations to conduct business; the Company is able to successfully manage the integration of its various business units with its own; there are not materially more closures or lockdowns related to the COVID–19 pandemic; the Company's subsidiaries obtain and maintain all necessary governmental and regulatory permits and approvals for the operation of their facilities and the development of cannabis products, and whether such permits and approvals can be obtained in a timely manner; the Company will be able to continue to successfully integrate Auxly Leamington's operations with its own, and whether the expected benefits of the acquisition materialize in the manner expected, or at all; the Company will be able to successfully launch new product formats and enter into new markets; there is acceptance and demand for current and future Company products by consumers and provincial purchasers; the Company will be able to increase revenues and achieve positive Adjusted EBITDA; and general economic, financial market, legislative, regulatory, competitive and political conditions in which the Company and its subsidiaries and partners operate will remain the same. Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2022 dated March 30, 2023.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by the Company. The forward-looking information is being provided for the purposes of assisting the reader in understanding the Company's financial performance, financial position and cash flows as at and for periods ended on certain dates and to present information about management's current expectations and plans relating to the future, and the reader is cautioned that such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

______________________________

1 Headset Canadian Insights data, provided as of March 8, 2023

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/auxly-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-outlook-for-2023-301786942.html

SOURCE Auxly Cannabis Group Inc.

FAQ

What were Auxly's total net revenues for 2022?

Auxly reported total net revenues of $94.4 million for the year ended December 31, 2022.

What is the adjusted EBITDA for Auxly for 2022?

Auxly's adjusted EBITDA for 2022 was negative $16.9 million, representing an improvement of $4.8 million from 2021.

What was the net loss for Auxly in 2022?

The net loss attributable to shareholders of Auxly for 2022 was $130.3 million.

How did Auxly perform in the Cannabis 2.0 market?

Auxly retained its position as the #1 licensed producer for Cannabis 2.0 products in Canada for the third consecutive year.

What is Auxly's outlook for 2023?

Auxly aims to increase net revenues by 15% in 2023, focusing on dried flower, pre-rolls, and improving gross profit margins.